Home › Compare › FRRSF vs ABBV
FRRSF yields 33.06% · ABBV yields 3.06%● Live data
📍 FRRSF pulled ahead of the other in Year 1
Combined, FRRSF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FRRSF + ABBV for your $10,000?
Foremost Lithium Resource & Technology Ltd., an exploration company, engages in the identification and development of mineral properties in Canada and the United States. It explores for lithium, silver, and gold properties. The company has 100% interests in the Zoro Lithium project that comprise three contiguous areas/claims with a total area of approximately 3,603 hectares located in Snow Lake, Manitoba; and the Winston property that includes 149 unpatented lode, the Ivanhoe and Emporio patented, and four unpatented mining claims located in Sierra County, New Mexico. It also holds an option agreement to acquire a 100% interest in the Jean Lake lithium-gold project that covers an area of 1002 hectares located to the north of Winnipeg, as well as 90% interests in the Hidden Lake project comprises five contiguous claims covering approximately 1,659.29 hectares located in the Northwest Territories. The company was formerly known as Far Resources Ltd. and changed its name to Foremost Lithium Resource & Technology Ltd. in January 4, 2022. Foremost Lithium Resource & Technology Ltd. was incorporated in 2005 and is headquartered in Vancouver, Canada.
Full FRRSF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.